Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture. / Gabel, D; Preusse, D; Haritz, D; Grochulla, F; Haselsberger, K; Fankhauser, H; Ceberg, Crister; Peters, H D; Klotz, U.

I: Acta Neurochirurgica, Vol. 139, Nr. 7, 1997, s. 606-612.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Gabel, D, Preusse, D, Haritz, D, Grochulla, F, Haselsberger, K, Fankhauser, H, Ceberg, C, Peters, HD & Klotz, U 1997, 'Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture', Acta Neurochirurgica, vol. 139, nr. 7, s. 606-612. https://doi.org/10.1007/BF01411994

APA

CBE

MLA

Vancouver

Author

Gabel, D ; Preusse, D ; Haritz, D ; Grochulla, F ; Haselsberger, K ; Fankhauser, H ; Ceberg, Crister ; Peters, H D ; Klotz, U. / Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture. I: Acta Neurochirurgica. 1997 ; Vol. 139, Nr. 7. s. 606-612.

RIS

TY - JOUR

T1 - Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

AU - Gabel, D

AU - Preusse, D

AU - Haritz, D

AU - Grochulla, F

AU - Haselsberger, K

AU - Fankhauser, H

AU - Ceberg, Crister

AU - Peters, H D

AU - Klotz, U

PY - 1997

Y1 - 1997

N2 - The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

AB - The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

KW - Boron neutron capture therapy

KW - glioma

KW - BSH

U2 - 10.1007/BF01411994

DO - 10.1007/BF01411994

M3 - Article

VL - 139

SP - 606

EP - 612

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

IS - 7

ER -